7-methoxy-2-(2'-thienyl)-4H-3,1-benzoxazin-4-one | 219773-61-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 7-methoxy-2-(2'-thienyl)-4H-3,1-benzoxazin-4-one
• 英文别名: 7-Methoxy-2-thiophen-2-yl-3,1-benzoxazin-4-one
• CAS: 219773-61-2
• 化学式: C₁₃H₉NO₃S
• 分子量: 259.285
• InChiKey: CELLCOYQAIILHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  76.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-methoxy-2-(2'-thienyl)-4H-3,1-benzoxazin-4-one 在 ammonium acetate 、 肼 、 三氯氧磷 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 23.0h， 生成 1-(7-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione
  参考文献：
  名称：

  The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcriptional activation. SAR of In vitro and In vivo studies

  摘要：

  We have developed novel orally active quinazoline analogues as inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. Among the derivatives prepared, 1-[2-(2-thienyl)quinazolin-4-ylamino]-3-methyl-3-pyrroline-2,5-dione (10) showed significant activity in an adjuvant-induced arthritis rat model by reducing the swelling by 65% in the non-injected foot. The synthesis, structure-activity relationship, and in vivo activity are described. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.047
• 作为产物：
  描述：

  2-氨基-4-甲氧基苯甲酸 以87%的产率得到7-methoxy-2-(2'-thienyl)-4H-3,1-benzoxazin-4-one
  参考文献：
  名称：

  Quinazoline analogs and related compounds and methods for treating

  摘要：

  本发明涉及具有抗炎作用的化合物，通常用于预防和/或治疗免疫炎症和自身免疫性疾病。这些化合物是喹唑啉类化合物。本发明还揭示了通过向需要的动物施用该化合物的有效量，优选地以药物组合物的形式，来预防和/或治疗炎症病况的方法。

  公开号：

  US05939421A1

文献信息

• Quinazoline analogs and related compounds and methods for treating
  申请人：Signal Pharmaceuticals, Inc.

  公开号：US05939421A1

  公开（公告）日：1999-08-17

  Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are quinazoline-containing compounds. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.

  本发明涉及具有抗炎作用的化合物，通常用于预防和/或治疗免疫炎症和自身免疫性疾病。这些化合物是喹唑啉类化合物。本发明还揭示了通过向需要的动物施用该化合物的有效量，优选地以药物组合物的形式，来预防和/或治疗炎症病况的方法。
• [EN] QUINAZOLINE ANALOGS AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS<br/>[FR] ANALOGUES DE QUINAZOLINE ET COMPOSES ASSOCIES ET METHODES POUR TRAITER LES TROUBLES INFLAMMATOIRES
  申请人：SIGNAL PHARMACEUTICALS, INC.

  公开号：WO1999001441A1

  公开（公告）日：1999-01-14

  (EN) Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are quinazoline-containing compounds. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.(FR) L'invention concerne des composés utiles de manière générale comme agents anti-inflammatoires et plus spécifiquement comme agents préventifs et/ou thérapeutiques pour les maladies immuno-inflammatoires et auto-immunes. Ces composés contiennent de la quinazoline. L'invention concerne également de méthodes pour prévenir et/ou traiter les états inflammatoires en administrant à un animal nécessitant un tel traitement une quantité efficace d'un des composés décrits, de préférence sous forme d'une composition pharmaceutique.

  该发明涉及一种具有抗炎作用的化合物，可用于预防和/或治疗免疫炎症和自身免疫疾病。这些化合物含有喹唑啉。本发明还揭示了通过向需要治疗的动物施用本发明的化合物的有效量，尤其是以药物组成物的形式，以预防和/或治疗炎症状况的方法。
• US5939421A
  申请人：——

  公开号：US5939421A

  公开（公告）日：1999-08-17
• US6150372A
  申请人：——

  公开号：US6150372A

  公开（公告）日：2000-11-21
• The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcriptional activation. SAR of In vitro and In vivo studies
  作者：Moorthy S.S. Palanki、Paul E. Erdman、Minghuan Ren、Mark Suto、Brydon L. Bennett、Anthony Manning、Lynn Ransone、Cheryl Spooner、Sonal Desai、Arnie Ow、Ryuichi Totsuka、Peter Tsao、Wataru Toriumi

  DOI：10.1016/j.bmcl.2003.08.047

  日期：2003.11

  We have developed novel orally active quinazoline analogues as inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. Among the derivatives prepared, 1-[2-(2-thienyl)quinazolin-4-ylamino]-3-methyl-3-pyrroline-2,5-dione (10) showed significant activity in an adjuvant-induced arthritis rat model by reducing the swelling by 65% in the non-injected foot. The synthesis, structure-activity relationship, and in vivo activity are described. (C) 2003 Elsevier Ltd. All rights reserved.